



### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

### Listing of Claims

1. (Currently amended) A mechanically stable biphasic injectable soft tissue augmentation composition comprising[[],]:

biocompatible micronized high density polyethylene particles having a size greater than ~~sixty~~ one-hundred microns[[],]; and,

a physiological carrier, and wherein the composition is injected into soft tissue.

2. (Cancelled)

3. (Cancelled)

4. (Previously presented) The composition of Claim 1, wherein the physiological carrier is polyvinylpyrrolidone, silicone oil, gelatin, collagen, fat, hyaluronic acid, saline, water or plasma.

5. (Cancelled)

6. (Cancelled)

7. (Previously Presented) The composition of Claim 1, wherein the physiological carrier is polyvinylpyrrolidone.

8. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.

9. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

10. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.

11. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value of 17.

12. (Cancelled)

13. (Previously presented) The composition of Claim 1 wherein the biocompatible micronized high density polyethylene particles and the physiological carrier are combined at a ratio of approximately 3:2 physiological carrier to biocompatible micronized high density polyethylene particles by weight.

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Currently amended) A mechanically stable biphasic injectable soft tissue augmentation composition comprising[[],]:

biocompatible micronized high density polyethylene particles having a size of greater than sixty microns; and,

a physiological carrier comprising polyvinylpyrrolidone, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100, and wherein the composition is injected into soft tissue.

23. (Previously presented) The composition of Claim 22 wherein the biocompatible micronized high density polyethylene particles and the physiological carrier are combined at a ratio of approximately 3:2 physiological carrier to biocompatible micronized high density polyethylene particles by weight.

24. (Cancelled)

25. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

26. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.

27. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value of 17.

28. (Previously presented) The composition of Claim 22, wherein the biocompatible micronized high density polyethylene particles have a size greater than eighty microns.

29. (Previously presented) The composition of Claim 22, wherein the biocompatible micronized high density polyethylene particles have a size greater than one-hundred microns.

30. (Cancelled)

31. (New) A mechanically stable biphasic injectable soft tissue augmentation composition comprising:

biocompatible micronized high density polyethylene particles having a size of greater than one hundred microns; and,

a physiological carrier comprising polyvinylpyrrolidone, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100, and wherein the composition is injected into soft tissue.